Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) announced that its FDA-approved Shield blood test for colorectal cancer (CRC) screening will be covered under Carelon Healthcare Services’ clinical guidelines effective November 15. Carelon, a major U.S. medical benefit manager and subsidiary of a large health insurer, expands access to Shield for adults 45 and older at average CRC risk.
According to Guardant Health, this policy raises total U.S. covered lives for Shield to about 90 million, or roughly 75% of eligible CRC screening patients. Shield is guideline‑recommended by ACS and NCCN, has over 200,000 real‑world tests performed, and has shown over 90% screening adherence.
Summary not available.
TwinStrand Biosciences announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in its patent infringement suit against Guardant Health (Nasdaq: GH), in favor of TwinStrand and the University of Washington.
The judgment preserves a November 2023 jury finding of willful infringement of two Duplex Sequencing patents across 11 Guardant products and services and awards more than $245.2 million in damages, accrued royalties and interest for infringement through May 31, 2026. This includes $83.4 million in jury damages through June 30, 2023, $19.5 million in supplemental damages, $119.4 million in accrued royalties at a 6% royalty rate, and $22.9 million in pre- and post-judgment interest.
The court ordered Guardant to pay a continuing 6% royalty on U.S. sales of the covered products from June 1, 2026, until patent expiry on March 15, 2033, with quarterly payments and sales accounting. The court also upheld the validity of the asserted claims of both TwinStrand patents and entered judgment on validity in TwinStrand’s favor.
Guardant Health (Nasdaq: GH) reported that its Board Compensation Committee approved inducement grants of restricted stock units (RSUs) for 149 new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The awards cover 46,044 shares of common stock with a grant date of August 3, 2026.
According to Guardant Health, the RSUs are granted under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment. One-third of each award vests annually on the anniversary of the vesting commencement date, subject to continued employment and the terms of the Inducement Plan and RSU agreements.
Guardant Health (Nasdaq: GH) reported second quarter 2026 revenue of $335.0 million, up 44% year over year, led by Oncology revenue of $219.1 million (+38%) on ~104,000 tests (+63%) and Screening revenue of $52.9 million, up over 250% on ~66,000 Shield tests. Biopharma & Data revenue rose 9% to $60.9 million. GAAP gross margin was 65%, with non-GAAP gross margin of 67%. The company posted a GAAP net loss of $120.1 million ($0.90 per share) and non-GAAP net loss of $56.2 million ($0.42 per share).
According to Guardant Health, 2026 revenue guidance increased to $1.34–$1.36 billion (36%–38% growth), with higher expectations for Oncology, Screening (Shield revenue of $218–$230 million, 270,000–285,000 tests) and low double-digit Biopharma & Data growth. The company highlighted multiple FDA approvals, inclusion of Shield in American Cancer Society screening guidelines, UnitedHealth Group coverage, and cash, cash equivalents and restricted cash of $1.2 billion at June 30, 2026.
Guardant Health (Nasdaq: GH) will participate in two upcoming investor conferences: the Canaccord Genuity 46th Annual Growth Conference in Boston, with a fireside chat on Wednesday, August 12 at 3:00 p.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York, with a fireside chat on Tuesday, September 15 at 7:45 a.m. ET. Interested parties can access live and archived webcasts via the Investors section of the Guardant Health website.
Guardant Health (Nasdaq: GH) announced a new tribute video featuring actor and cancer advocate Patrick Dempsey, honoring Americans who have died from colorectal cancer (CRC) and urging adults 45+ at average risk to get screened. The video highlights Guardant’s Shield blood test, described as an FDA-approved, non-invasive CRC screening option and the only blood test included in both American Cancer Society and National Comprehensive Cancer Network guidelines. According to Guardant Health, real-world experience in about 200,000 patients shows Shield has over 90% test completion, suggesting higher adherence than other screening methods. Shield is intended for average-risk individuals 45 or older and a positive result should be followed by colonoscopy.
Guardant Health (Nasdaq: GH) announced it will report second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via the company’s investor relations website, with a replay available.
Guardant Health (Nasdaq: GH) announced that UnitedHealth Group now covers its FDA-approved Shield blood test for primary colorectal cancer screening in average-risk adults aged 45 and older. This policy makes United the first major U.S. commercial insurer to cover Shield for this population.
Approximately 40 million Americans are enrolled in UnitedHealth plans, contributing to over 100 million total covered lives with access to Shield. The test requires only a routine blood draw and is the first and only FDA-approved blood test included in both ACS and NCCN colorectal cancer screening guidelines.
Guardant Health (Nasdaq: GH) received FDA approval of its blood-based Guardant360 CDx test as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS (zongertinib) in adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
This is the 27th CDx indication for Guardant360 CDx globally and is supported by broad Medicare and commercial payer coverage representing over 300 million covered lives.